Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01113515
Recruitment Status : Unknown
Verified April 2015 by Novalead Pharma Private Limited.
Recruitment status was:  Active, not recruiting
First Posted : April 30, 2010
Last Update Posted : April 15, 2015
Information provided by (Responsible Party):
Novalead Pharma Private Limited

Brief Summary:
The purpose of this study is to determine safety and efficacy of a new gel formulation of Esmolol hydrochloride (Galnobax®) for the treatment of Diabetic Foot Ulcer (DFU). The study will compare number and types of adverse events occured, rates of wound closure and percentage of wounds closed in Galnobax treated groups versus placebo group.

Condition or disease Intervention/treatment Phase
Diabetic Foot Ulcer Drug: Esmolol hydrochloride Drug: Placebo gel Phase 1 Phase 2

Detailed Description:
This is an interventional, placebo-controlled, randomized, double-blinded, dose comparison, phase I/II study of Galnobax® in subjects with diabetic foot ulcers. Additionally the effect of dosage and frequency of application will also be studied . The total trial duration per subject is 25 weeks which comprises of 1 week for screening, 12 weeks of treatment and 12 weeks of follow-up.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: An Interventional, Placebo-Controlled, Randomized, Double-blinded Dose Comparison, Phase I/II Study to Determine the Safety and Efficacy of a New Gel Formulation of Esmolol Hydrochloride (Galnobax®) for the Treatment of Diabetic Foot Ulcer (DFU)
Study Start Date : February 2014
Estimated Primary Completion Date : September 2015
Estimated Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo gel
Drug: Placebo gel
Other Name: Placebo control

Experimental: Galnobax 20% QD
Esmolol Hydrochloride (Galnobax) 20% gel once daily
Drug: Esmolol hydrochloride
Other Name: Galnobax-QD

Experimental: Galnobax 20% BID
Esmolol Hydrochloride (Galnobax) 20% gel twice daily
Drug: Esmolol hydrochloride
Other Name: Galnobax-20%

Experimental: Galnobax 14% BID
Esmolol Hydrochloride (Galnobax) 14% gel twice daily
Drug: Esmolol hydrochloride
Other Name: Galnobax-14%

Primary Outcome Measures :
  1. Safety outcome [ Time Frame: Till end of follow up period (Week 25) ]
    Incidence of adverse events (AEs) till end of follow-up phase

Secondary Outcome Measures :
  1. Efficacy outcome [ Time Frame: Till end of treatment (Week 12) ]
    To evaluate the change from baseline in area and volume of ulcers at Week 12 and to compare the time taken for healing and closure of wound in different groups from baseline

Other Outcome Measures:
  1. Pharmacokinetics [ Time Frame: Till end of treatment ]
    Pharmacokinetic profile of Galnobax® in subset of patients suffering from DFU

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 95 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects aged 18 to 95 years, inclusive, with Type 1 or Type 2 diabetes undergoing therapy for glycemic control
  • Subjects having below knee ulcer of at least 4 week and maximum of 52 weeks duration which is a full thickness ulcer without exposure of bone, muscle, ligaments, or tendons
  • Ulcer should be clinically non-infected
  • Ulcer area (length x width) measurement between 1.5 cm2 and 10 cm2, inclusive and post debridement ulcer area less than or equal to 12 cm2.
  • Full-thickness ulcer of Grade 1 or Grade 2 as per Wagner's classification system
  • Recently debrided ulcer (2 weeks prior to screening) and post debridement ulcer free of necrotic debris, foreign bodies, sinus tracts, tunneling, and undermining, comprised of healthy vascularized tissue as determined by the Investigator
  • Inability to perceive 10 grams pressure using Semmes-Weinstein 5.07 monofilament in the peri-ulcer area
  • Ankle Brachial index between 0.7 and 1.2

Exclusion Criteria:

  • Actively infected ulcers with or without purulent discharge, ulcers with exposed bone or associated with osteomyelitis.
  • Subjects having cellulitis, ischemic or gangrenous ulcers in the opinion of the Investigator
  • Glycosylated hemoglobin (HbA1C) >12%
  • Diagnosed and/ currently unstable hypotension, heart block, cardiac failure, and other cardiac complications
  • Subject diagnosed with cancer undergoing chemotherapy
  • Revascularization surgery 4 weeks prior to signing the ICF
  • Renal failure as defined by serum creatinine >3.0 mg/dL or renal insufficiency requiring frequent dialysis
  • Poor nutritional status as measured by serum albumin <3.0 g/dL
  • Active Charcot or other structural deformity that would prevent adequate off-loading of the study foot

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01113515

United States, Rhode Island
VA New England Health Care Division
Providence, Rhode Island, United States, 02908
S.L. Raheja Hospital
Mumbai, Maharashtra, India, 400016
Deenanath Mangeshkar Hospital & Research Center
Pune, Maharashtra, India, 411004
M V Hospital for Diabetes Pvt. Ltd.
Chennai, Tamil Nadu, India, 600 013
Hospital Kuala Lumpur
Kuala Lumpur, Malaysia
Sponsors and Collaborators
Novalead Pharma Private Limited
Principal Investigator: Vickie R Driver, DPM FACFAS Providence Veteran Affairs Medical Center, RI

Responsible Party: Novalead Pharma Private Limited Identifier: NCT01113515     History of Changes
Other Study ID Numbers: Novalead-Galnobax-0210
First Posted: April 30, 2010    Key Record Dates
Last Update Posted: April 15, 2015
Last Verified: April 2015

Keywords provided by Novalead Pharma Private Limited:
Diabetic foot ulcer
Diabetic wound
chronic non healing ulcer

Additional relevant MeSH terms:
Diabetic Foot
Foot Ulcer
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs